eFFECTOR Therapeutics, Inc.
EFTRDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001828522
eFFECTOR Therapeutics, Inc. was delisted in 2026; its insiders filed their last Form 4 on Jun 13, 2024; 1 institution reported holding it in 13F filings for Q4 2025, worth $0 in total; no superinvestor held it.
13F holders, Q4 2025
Institutional positions in eFFECTOR Therapeutics, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
EFTR is no longer listed, so this page shows Q4 2025. 13F filings for later quarters list far fewer holders.
- Institutional holders
- 1
- 0 vs. Q3 2025
- Shares held
- 12
- 0 (0.0%) vs. Q3 2025
- Total value
- $0
- $0 vs. Q3 2025
- New holders
- 0
- 0 more added
- Sold out
- 0
- 0 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting EFTR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $0 |
| Q1 2026 | 1 | $0 |
| Q4 2025 | 1 | $0 |
| Q3 2025 | 1 | $0 |
| Q2 2025 | 1 | $0 |
| Q1 2025 | 1 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 3 | $4.33K |
| Q2 2024 | 18 | $251.1K |
| Q1 2024 | 17 | $13.5M |
| Q4 2023 | 24 | $5.45M |
| Q3 2023 | 29 | $14.0M |
| Q2 2023 | 33 | $20.2M |
| Q1 2023 | 26 | $9.94M |
| Q4 2022 | 30 | $10.4M |
| Q3 2022 | 27 | $13.7M |
| Q2 2022 | 24 | $33.9M |
| Q1 2022 | 19 | $89.7M |
| Q4 2021 | 18 | $174.2M |
| Q3 2021 | 12 | $187.9M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding eFFECTOR Therapeutics, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Proathlete Wealth Management LLC | 12 | $0 | 0.00% | 00.0% | Unchanged |